Please login to the form below
Moderna
This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.
New data from Moderna supports COVID boosters
Waning immunity from its mRNA jab “support benefit” of a booster shot, says Moderna, while international scientists publish plea for evidence over politics. ... While the reduction in incidence rates was not significant, there is a “numerical
Latest news
-
UK announces COVID boosters for a “bumpy winter” ahead
Where the Pfizer vaccine is unavailable, a half-dose of Moderna can be used and for anyone unable to receive the Pfizer or Moderna vaccines due to allergies, the AstraZeneca vaccine
-
FDA opens door to COVID-19 booster jabs
The FDA has amended its emergency use authorisations for both approved mRNA vaccines – Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax – for use as a booster/third jab for “certain immunocompromised ... Moderna has recently published data
-
BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
The company aims to develop a vaccine candidate and also boost mRNA manufacturing capabilities on the African continent
-
Moderna launches phase 1/2 study of mRNA-based flu vaccine
The flu vaccine candidate – known as mRNA-1010 – is Moderna’s first seasonal influenza vaccine to enter the clinic. ... viruses, such as influenza, SARS-CoV-2 and RSV,” said Stéphane Bancel, chief executive officer of Moderna.
-
J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant
Earlier this week, Moderna announced that its COVID-19 vaccine showed promising activity against COVID-19 variants in lab studies, including the Delta variant. ... According to Moderna, its mRNA-based vaccine showed activity against all variants tested,
UK announces COVID boosters for a “bumpy winter” ahead
FDA opens door to COVID-19 booster jabs
BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
Moderna launches phase 1/2 study of mRNA-based flu vaccine
J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant
More from news
Approximately 53 fully matching, plus 112 partially matching documents found.
Latest Intelligence
-
Fair representation in research matters to the sector and to society
In the US, both Pfizer and Moderna worked with community organisations to increase representation in the COVID-19 vaccine trials.
-
The new reality of building a corporate brand in pharma
Until the likes of Pfizer, AstraZeneca and Moderna started to have their coronavirus vaccines approved, the companies behind the medicines were rarely recognised by the public. ... The pharmaceutical and biotech company Moderna was virtually unknown to
-
Rare genetic diseases – what’s in store for 2021?
So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University vaccines have all received approval in the UK and other countries for the very disease that put all these changes into
-
COVID-19: the race to find a vaccine
Moderna was the first group to test a vaccine in humans, using its mRNA platform to enter the clinic in record time. ... Moderna thinks its vaccine could be available to healthcare professionals as early as the autumn, but the accepted timeline for
-
Developing a COVID-19 vaccine
At the front of the race is Cambridge, Massachusetts-based biotech company Moderna, which dosed the first patient in the US in March with its COVID-19 vaccine candidate. ... To win approval for public use, a larger phase 2 trial is need, which Moderna
Fair representation in research matters to the sector and to society
The new reality of building a corporate brand in pharma
Rare genetic diseases – what’s in store for 2021?
COVID-19: the race to find a vaccine
Developing a COVID-19 vaccine
More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
Horning has also recently joined the board of directors at Moderna, a clinical-stage biotechnology company based in Cambridge, Massachusetts.
-
Tony de Fougerolles joins Evox Therapeutics as CEO
Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
-
Medicxi appoints former GSK chair Moncef Slaoui
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
-
MIT chief financial officer joins Moderna Therapeutics
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
-
PureTech Health appoints chief scientific officer
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
Tony de Fougerolles joins Evox Therapeutics as CEO
Medicxi appoints former GSK chair Moncef Slaoui
MIT chief financial officer joins Moderna Therapeutics
PureTech Health appoints chief scientific officer
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Clinical trials and the diversity principle
The following month, it happened again. Cambridge, Massachusetts-based Moderna said it had slowed enrolment in its phase 3 COVID-19 vaccine trial to ensure they were getting a representative population. ... Moderna effectively sacrificed potential sales,
-
Mistrust in medical research: a patient perspective
15]. In fact, Moderna slowed down recruitment for its COVID-19 vaccine trial specifically to address a shortfall in recruitment from ethnically diverse populations for an illness that has been shown
-
Is the world ready for a COVID-19 vaccine?
Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. ... Since this initial announcement, other good news in vaccine development has followed, with companies and
-
Hanover Communications
Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results.
Hanover Communications
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- OPEN Health Acquires ARK
- Live Webinar: Artificial Intelligence for Improving Patient Outcomes & Operational Efficiency
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- AstraZeneca chooses Ireland for $360m manufacturing site
- Building the perfect behaviour-change buffet
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- David Hunt launches independent agency The Considered
- Lucid Group celebrates a double win at Communiqué 2021
- Live Webinar: Driving Healthcare Decisions with Natural Language Processing
- US orders 1.4 million more doses of Regeneron antibody cocktail
PMHub
11 London
The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
